Document:

SEC Connect

 

Exhibit 10.7

 

FIRST AMENDMENT TO THE LICENCE AGREEMENT

 

THIS
FIRST AMENDMENT to the LICENSE AGREEMENT with an Effective Date of
October 15, 2014 is made as of this July 6, 2015 (“Effective
Date of the Amendment”), by and between the UNIVERSITY OF
MISSISSIPPI, and CHROMADEX, INC. concerning a blue green algae
technology.

 

The
parties hereby agree to the following change to the LICENSE
AGREEMENT:

 

APPENDIX
A (PATENTS) is revised to add China, Italy, Finland, Sweden,
Austria, India, Norway, Poland and Denmark to the list of
International Filing and Issued Patents for UM1410. The revised
list is as follows:

 

UM1410:                       

Potent
Immunostimulants from Microalgae

 

USSN:
10/332,323

Issued
Patent: 7,205,284

Issued:
4/17/2007

Expiration:
3/9/22

 

International
Filings and Issued Patents:

 

	
 Australia  

	
 2001273330

	
 Canada

	
 2412600

	
 France  

	
 1301191

	
 Germany

	
 601 15
654.4

	
 Netherlands

	
 1301191

	
 South
Korea  

	
 10-08314080000

	
 Great
Britain 

	
 1301191

	
 Mexico

	
 254542

	
 China

	
 ZL01814316.4

	
 Italy

	
 48189
BE2006

	
 Finland

	
 1 301
191

	
 Sweden  

	
 1 301
191

	
 Austria  

	
 E
311892

	
 India   

	
 214154 

	
 Norway 

	
 329221 

	
 Poland   

	
 203814 

	
 Demark 

	
 1 301
191 

 

 

 

 

IN
WITHNESS WHEREOF, the parties hereto have duly executed this
License Agreement as of the date first above written.

 

	
UNIVERSITY OF
MISSISSIPPI

	
 

	
 

	
 

	
/s/ Walter G. Chambliss,
Ph.D.
 Walter
G. Chambliss, Ph.D.

Director
of Technology Management

Office
of Research & Sponsored Programs

	

July 27, 2015

Date

 

 

 

Acknowledged
by:

 

	
/s/ David S. Pasco,
Ph.D.

	

August 4, 2015

	
Davis S. Pasco,
Ph.D. 

	
Date

	
Assistant Director,
National Center for Natural Products Research

	
 

 

 

	
/s/ David D Allen,
Ph.D.  

	
8/4/15

	
David D Allen,
Ph.D.

	
Date

	
Dean, School of
Pharmacy

	
 

 

 

CHROMADEX,
INC.

 

	
 /s/ Frank Jaksch

	
July 28,
2015

	
 Frank
Jaksch 

	
Date

	
 Chief Executive
OfficerSEC Connect

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 of
the

Securities Act of 1934, as amended.

 

Exhibit 10.8

 

SECOND AMENDMENT TO THE LICENSE
AGREEMENT BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AND
CHROMADEX INC.

 

This second amendment (the “Second
Amendment”), dated
December 31st, 2015 (the “Effective
Date”), is made by and
between The Regents of the University of California
(“The Regents”), a California corporation having its
statewide administrative offices at 1111 Franklin Street,
12th
Floor, Oakland, California 94607-5200,
acting through the offices of The University of California, Irvine
located at 5171 California Ave, Suite 150 CA 92697-7700 and
ChromaDex
Inc.
(“Licensee”)
having a principal place of business at 10005 Muirlands Blvd, Suite
G, Irvine, CA 92618 and amends the license agreement with Licensee,
dated September 8, 2011 with UC Agreement Control
Number 2012-04-0120 (the
“License
Agreement”).

 

RECITALS

 

WHEREAS, the parties desire to
amend the diligence items of the License
Agreement;

 

NOW THEREFORE, in consideration
of the foregoing premises and the mutual promises, covenants, and
agreements hereinafter set forth, and notwithstanding any previous
provisions in the License Agreement, all parties to this Second
Amendment mutually agree to amend the License Agreement as
follows:

 

1. 

Amend Paragraph 10.7 of the License
Agreement to reflect a new development schedule by replacing this
paragraph in its entirety with the following:

 

“10.7 The Licensee, its Affiliates
or Sublicensees will, or will cause a Third Party to develop a
Non-Pharmaceutical Licensed Product according to the following
development schedule:

 

10.7.1
Complete safety studies by December 31, 2015;

10.7.2
Complete efficacy studies no later than June 30, 2016;

10.7.3
Complete stability studies no later than June 30, 2016;
and

10.7.4
Complete a first commercial sale by December 31, 2016.

 

The
rights of The Regents detailed in Paragraph 10.4 and the rights of
the Licensee in Paragraph 10.5 of this Agreement also apply to the
diligence items in this Paragraph 10.7. Licensee will report to The
Regents completion of the above events within thirty (30) days of
their completion”

 

2. Amend Paragraph 6.2 of the License Agreement to update
milestone payment deadlines by replacing this paragraph in its
entirety with the following:

 

“6.2. For
each Non-Pharmaceutical Licensed Product reaching the milestones
indicated below, The Licensee must make the following milestone
payments to The Regents. All amounts due under this section shall
be paid within thirty (30) days of receipt of invoice from The
Regents. Milestone payments are due from Licensee irrespective of
whether the milestone listed below was reached by the Licensee
itself, a third party acting on Licensee’s behalf, or by a
Sublicensee or Affiliate.

 

 

 

 

 

i. 

[...***...]
Dollars ($[...***...]) due upon completion of safety
studies.

 

ii. 

[...***...]
Dollars ($[...***...]) due upon completion of efficacy
studies.

 

iii. 

[...***...]
Dollars ($[...***...]) due upon completion of stability
studies.

 

iv. 

[...***...]
Dollars ($[...***...]) due upon the first commercial
sale.

 

3. 

All other terms and
conditions of the License Agreement remain the same.

 

This Second Amendment may be executed in two or more counterparts,
each of which shall be deemed an original but all of which together
shall constitute one and the same instrument.  Facsimile,
Portable Document Format (PDF) or photocopied signatures of the
Parties will have the same legal validity as original
signatures.

 

IN WITNESS WHEREOF, the parties have executed this First Amendment
by their duly authorized representatives for good and valuable
consideration.

 

	
 CHROMADEX,
INC.

	
 

	
 THE
REGENTS OF THE UNIVERSITY OF CALIFORNIA

	
 

	
 

	
 

	
 By: /s/ Troy
Rhonemus

 Name: Troy Rhonemus

 Title: COO 

 Date: 1/5/2016    

	
 

	
 By:/s/ Ronnie
Hanecak

 Name: Ronnie Hanecak,
PhD  

 Title: Assistant Vice
Chancellor 

 Date: January 4, 2016

 

 

 

 
***Confidential Treatment
RequestedSEC Connect

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 of
the

Securities Act of 1934, as amended.

 

Exhibit 10.9

SECOND ADDENDUM TO THE NIAGEN®
SUPPLY AGREEMENT
BETWEEN

NECTAR7 LLC AND CHROMADEX, INC.

This Second Addendum (the “Second Addendum”),
effective and binding as of the last date of signing of this Second
Addendum (“Second Addendum
Effective Date”), is attached to and forms part of the SUPPLY
AGREEMENT (the “Agreement”) dated August 28, 2015 and
the First Addendum dated September 30, 2015, made by and between
ChromaDex, Inc., a California corporation, having a principal place
of business at 10005 Muirlands Blvd, Suite G, Irvine, CA 92618
(“Seller”) and Nectar7 LLC, a Delaware limited liability
company, with principal
offices located at 12526 High Bluff Drive, Suite 210, San Diego, CA
92130 (“Buyer”). To the
extent that any of the terms or conditions contained in this Second
Addendum may contradict or conflict with any of the terms or
conditions of the Agreement or the First Addendum, it is expressly
understood and agreed that the terms of this Second Addendum shall
take precedence and supersede the Agreement and First
Addendum.

RECITALS

WHEREAS, the parties desire to
further amend the Agreement and First Addendum as provided
herein;

 

NOW THEREFORE, for good and
valuable consideration, the receipt of which is hereby
acknowledged, the parties agree as follows:

 

1.            

Amend the
Definitions for “Excluded Field” and “Excluded
Products” by replacing them in their entirety with the
following definitions:

 

“Excluded Field” means the
Doctor Channel, the Multi-Level Marketing Channel and the Direct
Response Channel and the following retailers or their applicable
operating affiliates (each a “Retailer”): Costco
Wholesale Corporation (“Costco”), Wal-Mart Stores, Inc.
(“Walmart”), Walgreens Boots Alliance, Inc.
(“Walgreens”), Meijer, Inc. (“Meijer”),
Shopko Stores Operating Co., LLC (“Shopko”), Publix
Super Market’s, Inc. (“Publix”), Ahold U.S.A.,
Inc. (“Ahold”), QVC, Inc. (“QVC”), eVine
Live, Inc. (“eVine”), HSNi, LLC (“HSN”),
Target Corporation (“Target”), but excluding CVS
locations in Target Stores, The Kroger Co. (“Krogers”),
Wegmans Food Markets, Inc. (“Wegmans”), Ulta Salon,
Cosmetics & Fragrance, Inc. (“Ulta”), Vitacost.com,
Inc. (“VitaCost”),
the “Doctor
Channel” is defined herein as the sale of nutritional
supplements through licensed healthcare practitioners. The
“Multi-Level
Marketing Channel” is defined herein as the sale of
the Finished Products through a network of independent marketing
representatives. The “Direct Response Channel”
is defined here in as the marketing and advertising of the Finished
Product through direct response television and radio advertisements
of any length or format intended to reach one or more potential
consumers asking such consumers to purchase from or respond
directly to Buyer or Buyer’s agents via a website, telephone
number or other medium to purchase the Finished Products.
Additional channels may be added to this definition of
“Excluded Field” at any time by the Seller, in its sole
discretion, upon thirty (30) days prior written notice to
Buyer.”

 

“Excluded Products” means
topical skincare or cosmetics products, any and all dietary
supplements in the form of an energy shot or a melt (melting or
dissolvable tablet or delivery system), the combination of
NIAGEN® with
pterostilbene, the combination of NIAGEN® with Choline
and/or Betaine and/or dimethylglycine (DMG) (all forms), unless the
Finished Product is a multi-vitamin, and Finished Products with
“Methyl Donor” claims. Seller may add additional
products to this definition of “Excluded Products”, in
its sole discretion, upon written notice to Buyer; provided, that, such added products do
not impair the rights of Buyer to purchase the Product for the
applications set forth on Exhibit B."

 

 

-1-

 

 

2.            

Amend Section 2 of
the Agreement by adding Section 2.3 which states the
following:

 

“2.3              

Right to Sell Limitation. For
ninety (90) days from January 8, 2016, Buyer agrees not to have any
discussions with retailers regarding Finished Products. As
consideration for Buyer’s agreement, for one (1) year from
the Second Addendum Effective Date, Buyer shall receive
[...***...] percent
([...***...]%) of revenue Seller generates from
NIAGEN®
sales to
[...***...].”

3.            

Amend Exhibit B -
Exclusivity Rights for Finished Products in the First Addendum, as
they pertain to the Product Application for the combination of
NIAGEN®
and collagen. The Minimum
Revenues/Obligations “Minimum Revenues” are amended in
that the Minimum Revenue requirement for 2016 is
$[...***...] instead of $[...***...].

4.            

Amend Exhibit B -
Exclusivity Rights for Finished Products, as it pertains to the
Product Application for wound healing. The Minimum
Revenues/Obligations “Minimum Revenues” are replaced in
its entirety with the language set forth below and the Term
increased from five (5) to ten (10) years.

 

 

***Confidential Treatment
Requested

 

-2-

 

 

EXHIBIT
B

Exclusivity
Rights

	

Product

	
 

	

Product Application

	
 

	

 

Term

	
 

	

Exclusivity Area/Region

	
 

	

Minimum

Revenues/Obligations

“Minimum Revenues”

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

NIAGEN®

	
 

	

Finished Products for wound healing, including prevention and
treatment, with the exception of cosmetics, prescription drugs
and Over-the-Counter (OTC) therapeutic category subtopics:
Acne; Dandruff; Seborrheic Dermatitis; Psoriasis; Skin Protectant;
Sunscreen.

 

	
 

	

Ten (10) years

	
 

	

The world

	
 

	

2016: Minimum Revenues are
waived but Buyer must continue development and demonstrate proof of
concept to the reasonable satisfaction of Seller by year
end.

2017: Minimum Revenues are
waived but Buyer must launch at least one (1) Finished Product
containing the Product.

2018: Minimum Revenue of
$[...***...]

2019: Minimum Revenue of
$[...***...]

2020: Minimum Revenue of
$[...***...]

2021: Minimum Revenue of
$[...***...]

2022: Minimum Revenue of
$[...***...]

2023: Minimum Revenue of
$[...***...]

2024: Minimum Revenue of
$[...***...]

2025: Minimum Revenue of
$[...***...]

 

Every year thereafter shall be negotiated in good
faith.

 

5.            

Amend Exhibit B -
Exclusivity Rights for Finished Products, as it pertains to the
Product Application for Dietary Supplement in the form of a table
or capsule. Indonesia shall be added as a country for exclusivity.
The Exclusivity Area/Region shall include the language set forth
below.

 

 
***Confidential Treatment
Requested

 

-3-

 

 

EXHIBIT B

Exclusivity Rights

 

	

Product

	
 

	

Product Application

	
 

	

 

Term

	
 

	

Exclusivity Area/Region

	
 

	

Minimum

Revenues/Obligations

“Minimum Revenues”

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

NIAGEN®

	
 

	

Dietary Supplement in the form of a tablet or capsule

 

	
 

	

Seller launches product within 1 year of Effective Date in each
country or loses exclusivity for that specific country

	
 

	

Philippines, Taiwan, Hong Kong (not all of China), Singapore,
Indonesia

	
 

	

For 6 months from Second Addendum Effective Date, Minimum Revenues
are waived but Buyer must launch at least one Finished Product
containing the Product:

 

$[...***...] for Year 1 (Year 1 begins 6 month after the
Effective Date)

 

$[...***...] for Year
2

 

$[...***...] for Year
3

 

$[...***...] for Year
4

 

$[...***...] for any
single twelve (12) month period between the Second Addendum
Effective Date and 2020.

 

6.            

Amend Exhibit B -
Exclusivity Rights for Finished Products, by adding a Product
Application for pets. Buyer shall have exclusivity rights to sell
Finished Products to pets, provided that there is also one (1)
third party entitled to sell Finished Products within the Product
Application for pets.

 

 
***Confidential Treatment
Requested

 

-4-

 

 

EXHIBIT B

Exclusivity Rights

 

	

Product

	
 

	

Product Application

	
 

	

 

Term

	
 

	

Exclusivity Area/Region

	
 

	

Minimum

Revenues/Obligations

“Minimum Revenues”

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

NIAGEN®

	
 

	

Finished Products for pets, with the exception of one (1) third
party who may also sell Finished Products within this Product
Application

	
 

	

Three (3) years

	
 

	

The world

	
 

	

2016: Minimum Revenues of
$[...***...]

2017: Minimum Revenues of
$[...***...]

2018: Minimum Revenue of
$[...***...]

 

Every year thereafter shall be negotiated in good
faith.

 

7.            

Amend Exhibit B -
Exclusivity Rights for Finished Products, as it pertains to the
Product Application for sports hydration beverages to include
energy drinks and waters, including vitamin waters.

 

 

 
***Confidential Treatment
Requested

 

-5-

 

 

EXHIBIT B

Exclusivity Rights

 

 

	

Product

	
 

	

Product Application

	
 

	

 

Term

	
 

	

Exclusivity Area/Region

	
 

	

Minimum

Revenues/Obligations

“Minimum Revenues”

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	

NIAGEN®

	
 

	

Sports hydration beverages, energy drinks, and waters, including
vitamin waters all with a Nutrition Facts label and a net quantity
contents greater than 2 oz.

 

	
 

	

1 Year

	
 

	

United States

	
 

	

Meet with 1 potential customer and have made meaningful progress
toward deal to the reasonable satisfaction with Seller within 90
days of the Second Addendum Effective Date.

 

Exclusivity rights and obligation for each category will be
negotiated in good faith upon signed supply deal.

 

 

8.            

All other terms and
conditions of the Agreement and First
Addendum remain the same.

 

9.           

This
Second Addendum may be executed in two or more counterparts, each
of which shall be deemed an original but all of which together
shall constitute one and the same instrument.  Facsimile,
Portable Document Format (PDF) or photocopied signatures of the
Parties will have the same legal validity as original
signatures.

 

IN WITNESS WHEREOF, the parties have executed this Second Addendum
by their duly authorized representatives for good and valuable
consideration.

 

	
 CHROMADEX,
INC.     

	
 

	
 NECTAR7
LLC

	
 

	
 

	
 

	
By: /s/ Troy Rhonemus

Name: Troy Rhonemus

Title: COO

Date: 1/28/2016

	
 

	
By: /s/ David
D’Arcangelo

Name: David
D’Arcangelo

Title: Manager

Date: 1/28/16

 

 

 

 

-6-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]